JPRN-UMIN000004803已完成未知
A Double-Blind, Randomized Study of Minocycline for the Decision-Making Process in Young Adult Healthy Volunteer
Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 100 人开始时间: 2010年12月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 29years-old（—）
- 性别
- Male
入选标准
- •1.Healthy adult male
- •2.20 years old to 29 years old
- •3.Those who can obtain informed consent
排除标准
- •1. Those who ever have side effects by antibiotics including minocycline
- •2. Those who have severe disease in heart, liver or kidney.
- •3. Those who have a tendency to develop allergy
- •4. Those who have ever diagnosed psychiatric disorders.
- •5. Those who are judged not appropriate to this study by medical doctor in charge.
研究者
相似试验
招募中
3 期
Randomised Double Blind Controlled Trial of Minocycline in Japanese encephalitisCTRI/2010/091/006143ational Brain Research Centre, Manesar, Gurgaon144
进行中（未招募）
不适用
A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung CancerBrain metastases from Non-Small Cell Lung Cancer (NSCLC)EUCTR2010-019637-96-DEYMBiosciences INC88
Unknown
2 期
A clinical study of a monoclonal antibody Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non Small Cell Lung CancerCTRI/2010/091/000344Biocon India Limited on behalf of YM Biosciences Inc., Ontario, Canada.10
尚未招募
3 期
A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-IC patients with COVID-19 infectionsNL-OMON49946eids Universitair Medisch Centrum430
进行中（未招募）
1 期
A Randomized, Double-blind Pharmacokinetic Study of PF-05280014 Plus Taxotere and Carboplatin Versus Herceptin Plus Taxotere And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable HER2-Positive Breast Cancer - REFLECTIONS B327-04EUCTR2013-004679-11-ITPfizer Inc225